Regulatory PathRegulatory requirements compared

Active substances

Mineral oil + White petrolatum

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
REFRESH P.M.EYE OINT.57.3,42.5 %,%Eye ointment · Ophthalmic use1 TubeSAR 28.20Generic · OTCAbbVie IncValid
Indications — CHI Daman Drug Formulary

ALLERGIC CONJUCTIVITIS (AC); ANESTHESIA-SUPPORTIVE AGENTS/ EYE DRYNESS IN PATIENTS RECEIVING CONTINUOUS INFUSIONS OF NEUROMUSCULAR BLOCKERS.; BELL'S PALSY; SJOGREN'S SYNDROME; VIRAL CONJUNCTIVITS, HERPESVIRAL KERATITIS, HERPESVIRAL CONJUNCTIVITIS, VARICELLA KERATITIS, ZOSTER CONJUNCTIVITIS, ZOSTER KERATITIS, MEASLES KERATITIS AND KERATOCONJUNCTIVITIS, VIRAL CONJUNCTIVITIS, KERATITIS

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
REFRESH LACRI-LUBE0021088942.5 %; 57.3 %OINTMENT · OPHTHALMICABBVIE CORPORATION

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACREFRESH LACRI-LUBE OINTMENT$2.78813per GM19 Aug 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.